• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Tuberculosis Partnering 2009-2014 Product Image

Tuberculosis Partnering 2009-2014

  • Published: August 2014
  • Region: Global
  • 100 pages
  • CurrentPartnering

FEATURED COMPANIES

  • Abbott
  • Baxter International
  • Dainippon Sumitomo
  • Grifols
  • Mitsubishi Tanabe
  • Servier
  • MORE

The Tuberculosis Partnering 2009-2014 report provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in tuberculosis partnering deals
Top tuberculosis deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Tuberculosis Partnering 2009-2014 provides understanding and access to the tuberculosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of tuberculosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors tuberculosis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil READ MORE >

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in tuberculosis partnering

2.1. Introduction
2.2. Tuberculosis partnering over the years
2.3. Bigpharma tuberculosis dealmaking activity
2.4. Tuberculosis partnering by deal type
2.5. Tuberculosis partnering industry sector
2.6. Tuberculosis partnering by stage of development
2.7. Tuberculosis partnering by technology type
2.8. Disclosed financial deal terms for tuberculosis partnering
2.8.1 Tuberculosis headline values
2.8.2 Tuberculosis upfront payments
2.8.3 Tuberculosis milestone payments
2.8.4 Tuberculosis royalty rates

Chapter 3 – Leading tuberculosis deals

3.1. Introduction
3.2. Top tuberculosis deals by value
3.3. Top tuberculosis deals involving bigpharma

Chapter 4 – Dealmaking directory

4.1. Introduction

4.2. Company A-Z

4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 – Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

Table of figures

Figure 1: hepatitis partnering since 2009
Figure 2: Bigpharma – top 50 – tuberculosis deals 2009 to 2014
Figure 3: Bigpharma tuberculosis deal frequency – 2009 to 2014
Figure 4: Tuberculosis partnering by deal type since 2009
Figure 5: Tuberculosis partnering by industry sector since 2009
Figure 6: Tuberculosis partnering by stage of development since 2009
Figure 7: Tuberculosis partnering by technology type since 2009
Figure 8: Tuberculosis deals with a headline value
Figure 9: Tuberculosis deals with upfront payment values
Figure 10: Tuberculosis deals with milestone payments
Figure 11: Tuberculosis deals with royalty rates, %
Figure 12: Top tuberculosis deals by value since 2009
Figure 13: Top tuberculosis deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
Valeant
Warner Chilcott
Watson

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos